Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis

The article ‘‘Baricitinib: A Review in Moderate to Severe Atopic Dermatitis”, written by Sheridan M. Hoy was originally published electronically on the publisher’s internet portal (currently SpringerLink) on May 3, 2022 without open access. After publication in volume 23, issue 3, pages 409-420, Eli Lilly and Company requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Eli Lilly and Company. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party materials in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

The original article has been corrected.

留言 (0)

沒有登入
gif